“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.
The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
-
Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment
-
Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.
-
In March 2024, US-based Seyltx has finalized an agreement to acquire Algernon Pharmaceuticals' chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.
-
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is developing Haduvio™ (oral nalbuphine ER) for patients with chronic cough associated with idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. The company announced the start of its Phase 2b CORAL clinical trial, which will assess three doses of Haduvio against a placebo in around 160 IPF patients with chronic cough. This Phase 2b trial follows the successful Phase 2a CANAL trial, which showed a statistically significant 75.1% reduction in daytime cough frequency, representing a 52.5% difference from placebo (p<0.0001).
Cough in Idiopathic Pulmonary Fibrosis Overview
Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common symptom characterized by a persistent and often dry cough that worsens over time. It is a hallmark of the disease and can significantly impact a patient's quality of life. The cough in IPF is usually non-productive, meaning it does not produce mucus or phlegm.
Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight
Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
-
Orvepitant Maleate: NeRRe Therapeutics
-
Haduvio (nalbuphine ER): Trevi Therapeutics
-
ME-015 (Suplatast Tosilate): Melius Pharma AB
-
BI 1839100: Boehringer Ingelheim
Cough in Idiopathic Pulmonary Fibrosis Route of Administration
Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Cough in Idiopathic Pulmonary Fibrosis Molecule Type
Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
-
Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type
-
Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type
-
Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
-
Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
-
Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
-
Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type
DelveInsight's Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies
Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:
Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are - Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others.
Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:
The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
-
Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies
Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers
-
High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.
Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers
-
However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.
Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
-
Coverage: Global
-
Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others
-
Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others
-
Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
-
Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers
Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials
Table of Contents
1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction
2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary
3. Cough in Idiopathic Pulmonary Fibrosis Overview
4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)
7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)
8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)
9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products
10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment
11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cough in Idiopathic Pulmonary Fibrosis Key Companies
14. Cough in Idiopathic Pulmonary Fibrosis Key Products
15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs
16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers
17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion
18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
